Influenza is a disease known since antiquity that continuesto afflict large numbers of people and cause many deaths throughoutthe world. The annual epidemic and the continued threat of apandemic constitute a major infectious-disease problem.1,2,3,4,5,6,7,8Although the prevention of the spread of virus by ill personsand the removal of virus in transit in the environment couldtheoretically contribute to the control of influenza, effectivecontrol requires the optimal use of vaccines and antiviral drugs.At present, a vaccine and four antiviral drugs are approvedin the United States and many other countries for the preventionand treatment . . . [Full Text of this Article]
Vaccines
Inactivated Vaccines
Efficacy
Adverse Effects
Implementation
Live Attenuated Vaccine
Antiviral Drugs
Amantadine and Rimantadine
Antiviral Action
Pharmacokinetics
Adverse Effects
Efficacy
Dosage
Drug Resistance
Zanamivir and Oseltamivir
Antiviral Action
Pharmacokinetics
Adverse Effects
Efficacy
Drug Resistance
Recommendations for Use of Antiviral Drugs
Selection of an Antiviral Drug
Long-Term Care Facilities
Conclusions
Source Information
From the Department of Molecular Virology and Microbiology and the Department of Medicine, Baylor College of Medicine, Houston. This article does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
Address reprint requests to Dr. Couch at the Department of Molecular Virology and Microbiology, 1 Baylor Plaza, Houston, TX 77030, or at rcouch@bcm.tmc.edu.
References
This article has been cited by other articles:
Madjid, M., Miller, C. C., Zarubaev, V. V., Marinich, I. G., Kiselev, O. I., Lobzin, Y. V., Filippov, A. E., Casscells, S. W. III
(2007). Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34 892 subjects. Eur Heart J
28: 1205-1210
[Abstract][Full Text]
Galvani, A. P., Reluga, T. C., Chapman, G. B.
(2007). Long-standing influenza vaccination policy is in accord with individual self-interest but not with the utilitarian optimum. Proc. Natl. Acad. Sci. USA
104: 5692-5697
[Abstract][Full Text]
Weinberg, A., Walker, M. L.
(2005). Evaluation of Three Immunoassay Kits for Rapid Detection of Influenza Virus A and B. CVI
12: 367-370
[Abstract][Full Text]
Smitherman, H. F., Caviness, A. C., Macias, C. G.
(2005). Retrospective Review of Serious Bacterial Infections in Infants Who Are 0 to 36 Months of Age and Have Influenza A Infection. Pediatrics
115: 710-718
[Abstract][Full Text]
Hindiyeh, M., Levy, V., Azar, R., Varsano, N., Regev, L., Shalev, Y., Grossman, Z., Mendelson, E.
(2005). Evaluation of a Multiplex Real-Time Reverse Transcriptase PCR Assay for Detection and Differentiation of Influenza Viruses A and B during the 2001-2002 Influenza Season in Israel. J. Clin. Microbiol.
43: 589-595
[Abstract][Full Text]
Jeon, S. H., Kayhan, B., Ben-Yedidia, T., Arnon, R.
(2004). A DNA Aptamer Prevents Influenza Infection by Blocking the Receptor Binding Region of the Viral Hemagglutinin. J. Biol. Chem.
279: 48410-48419
[Abstract][Full Text]
Balicer, R. D, Huerta, M., Grotto, I.
(2004). Tackling the next influenza pandemic. BMJ
328: 1391-1392
[Full Text]
McSharry, J. J., McDonough, A. C., Olson, B. A., Drusano, G. L.
(2004). Phenotypic Drug Susceptibility Assay for Influenza Virus Neuraminidase Inhibitors. CVI
11: 21-28
[Abstract][Full Text]
Gaglani, M. J., Herschler, G. B.
(2004). Every Nose Counts: A New Influenza Vaccine for All Healthy Schoolchildren?. CLIN PEDIATR
43: 35-41
[Abstract]
Habib-Bein, N. F., Beckwith, W. H. III, Mayo, D., Landry, M. L.
(2003). Comparison of SmartCycler Real-Time Reverse Transcription-PCR Assay in a Public Health Laboratory with Direct Immunofluorescence and Cell Culture Assays in a Medical Center for Detection of Influenza A Virus. J. Clin. Microbiol.
41: 3597-3601
[Abstract][Full Text]
Halperin, S. A., Smith, B., Nolan, C., Shay, J., Kralovec, J.
(2003). Safety and immunoenhancing effect of a Chlorella-derived dietary supplement in healthy adults undergoing influenza vaccination: randomized, double-blind, placebo-controlled trial. CMAJ
169: 111-117
[Abstract][Full Text]
(2002). {blacktriangledown}Oseltamivir for influenza. DTB
40: 89-91
[Abstract][Full Text]
Rennels, M. B., Meissner, H. C., Committee on Infectious Diseases,
(2002). Technical Report: Reduction of the Influenza Burden in Children. Pediatrics
110: e80-e80
[Abstract][Full Text]
Tumpey, T. M., Garcia-Sastre, A., Mikulasova, A., Taubenberger, J. K., Swayne, D. E., Palese, P., Basler, C. F.
(2002). Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc. Natl. Acad. Sci. USA
99: 13849-13854
[Abstract][Full Text]
Ahmed, F., Singleton, J. A., Franks, A. L.
(2001). Influenza Vaccination for Healthy Young Adults. NEJM
345: 1543-1547
[Full Text]
Haley, C. E
(2001). Postexposure prophylaxis with inhaled zanamivir was efficacious for household contacts of people with influenza. Evid. Based Med.
6: 140-140
[Full Text]
Haley, C. E
(2001). Oseltamivir reduced new cases of influenza in household contacts of people with clinical or confirmed influenza. Evid. Based Med.
6: 141-141
[Full Text]
Drusano, G. L., Preston, S. L., Smee, D., Bush, K., Bailey, K., Sidwell, R. W.
(2001). Pharmacodynamic Evaluation of RWJ-270201, a Novel Neuraminidase Inhibitor, in a Lethal Murine Model of Influenza Predicts Efficacy for Once-Daily Dosing. Antimicrob. Agents Chemother.
45: 2115-2118
[Abstract][Full Text]
Coonrod, J. D.
(2001). Influenza : Will New Diagnostic Tests and Antiviral Drugs Make a Difference?. Chest
119: 1630-1632
[Full Text]
Previous
